Enrique Dilone - Amicus Therapeutics Vice President - Technical Operations
FOLD Stock | USD 11.86 0.43 3.76% |
President
Dr. Enrique Dilone Ph.D. RAC. is Vice President Technical Operations of Amicus Therapeutics Inc. From August 2009 to January 2011 he served as Senior Director Quality Control and Analytical Chemistry. Prior to joining Amicus Dr. Dilon served as Executive Director of Quality and Analytics at NovaDel Pharma a specialty pharmaceutical company developing oral spray formulations from February 2007 to August 2009 since 2011.
Age | 47 |
Tenure | 13 years |
Address | 47 Hulfish Street, Princeton, NJ, United States, 08542 |
Phone | 609 662 2000 |
Web | https://amicusrx.com |
Amicus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0704) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to -0.13. In addition to that, Return On Assets is expected to decline to -0.2. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 7.23, whereas Other Assets are forecasted to decline to about 41.8 M.Similar Executives
Found 11 records | PRESIDENT Age | ||
Michael Tang | Agilent Technologies | 50 | |
Jacob Thaysen | Agilent Technologies | 49 | |
Dominique Grau | Agilent Technologies | 65 | |
Henrik AncherJensen | Agilent Technologies | 59 | |
Robert McMahon | Agilent Technologies | 55 | |
Alicia Rodriguez | Agilent Technologies | N/A | |
Eilon Asculai | Mediwound | N/A | |
Rodney Gonsalves | Agilent Technologies | 58 | |
Samraat Raha | Agilent Technologies | 51 | |
Mark Doak | Agilent Technologies | 63 | |
Patrick Kaltenbach | Agilent Technologies | 53 |
Management Performance
Return On Equity | -1.07 | ||||
Return On Asset | -0.0612 |
Amicus Therapeutics Leadership Team
Elected by the shareholders, the Amicus Therapeutics' board of directors comprises two types of representatives: Amicus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amicus. The board's role is to monitor Amicus Therapeutics' management team and ensure that shareholders' interests are well served. Amicus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amicus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Hung Do, Senior Vice President - Discovery Biology | ||
Robert Essner, Independent Director | ||
John Kirk, Vice President - Regulatory Affairs | ||
David Clark, Chief Officer | ||
Andrew Mulberg, Vice President - Regulatory Strategy | ||
Craig Wheeler, Independent Director | ||
Daphne Quimi, Principal Accounting Officer, VP of Fin. and Corporate Controller | ||
Bradley Campbell, Pres and COO | ||
Burke Whitman, Independent Director | ||
Enrique Dilone, Vice President - Technical Operations | ||
John Crowley, Executive Chairman | ||
Dipal Doshi, Senior Vice President - Business Planning and Development | ||
Mark Baldry, Vice President of Global Marketing | ||
Margaret McGlynn, Independent Director | ||
Samantha Prout, Principal Accounting Officer, Controller | ||
Bradley MBA, President CEO | ||
Andrew Faughnan, Director Relations | ||
Diana Moore, Head Communications | ||
Kenneth Peist, Vice President - Legal and Intellectual Property | ||
Ken Valenzano, Senior Vice President - Preclinical Research | ||
Ted Love, Independent Director | ||
Jay Barth, Chief Medical Officer | ||
Jayne Gershkowitz, Vice President - Patient Advocacy & Public Policy | ||
Donald Hayden, Lead Independent Director | ||
Patrik Esq, Global Officer | ||
Michael Raab, Independent Director | ||
Sara Pellegrino, IR Contact Officer | ||
Willem Weperen, Regional Vice President and Country Manager, International | ||
Sol Barer, Independent Director | ||
Julie Yu, Vice President - Clinical Operations and Data Management | ||
Patrik Florencio, Global VP | ||
William Baird, CFO | ||
David Allsop, Senior Vice President - International | ||
Lynn Bleil, Independent Director | ||
Simon Harford, Chief Officer | ||
Ellen Rosenberg, General Counsel and Corporate Secretary | ||
Simon Jordan, Senior Vice President - International | ||
Jill Weimer, Senior Vice President of Discovery Research and Gene Therapy Science | ||
Glenn Sblendorio, Independent Director | ||
Jeffrey Castelli, Vice President - Program and Portfolio Management | ||
Kurt Andrews, Senior Vice President - Human Resources |
Amicus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amicus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.07 | ||||
Return On Asset | -0.0612 | ||||
Profit Margin | (0.38) % | ||||
Operating Margin | (0.03) % | ||||
Current Valuation | 3.67 B | ||||
Shares Outstanding | 295.38 M | ||||
Shares Owned By Insiders | 0.75 % | ||||
Shares Owned By Institutions | 99.25 % | ||||
Number Of Shares Shorted | 32.4 M | ||||
Price To Earning | (9.18) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 1.353 | Quarterly Revenue Growth 0.306 | Return On Assets (0.06) | Return On Equity (1.07) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.